Pharmaceutical

Health Canada approves Novartis’ Fabhalta for PNH with haemolytic anaemia

Health Canada has approved Novartis Canada’s Fabhalta (iptacopan capsules) as the first oral monotherapy to treat adults with PNH.

Feb 15, 2025 - 06:00
Health Canada approves Novartis’ Fabhalta for PNH with haemolytic anaemia
Health Canada has approved Novartis Canada’s Fabhalta (iptacopan capsules) as the first oral monotherapy to treat adults with PNH.
Read the original article

Tags:

Previous Article

Newleos secures $93.5m for neuropsychiatric treatments

Next Article

Revolutionary approaches to drug design: how AI is transforming life sciences

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Y-mAbs’ Danyelza injection receives marketing approval in Brazil

Y-mAbs’ Danyelza injection receives marketing approval ...

May 24, 2023

STAT+: How the political right came to back psychedelics to treat trauma

STAT+: How the political right came to back psychedelic...

Jul 10, 2023

In a showy hearing, Bernie Sanders gets few answers about lower drug prices

In a showy hearing, Bernie Sanders gets few answers abo...

Feb 9, 2024